18 completed, 5 recruiting, 3 active not recruiting, 1 not yet recruiting. 30 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 30 | Completed 18, Recruiting 5, Active not recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 9 | Completed 4, Recruiting 3, Terminated 1, Unknown 1 |
Follow Rapamycin: new trials by email Literature Review of Rapamycin trials Research Report on Rapamycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Gerotherapeutic Interventions for Healthspan Improvement Rapamycin, Naltrexone, Metformin - Healthspan Improvement, Aging | Phase 3 | Completed | AgelessRx | 26 | 2025-07-23 | 2026-10-30 |
| Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 Low-dose sirolimus, Placebo - Long COVID-19 | Phase 3 | Recruiting | Icahn School of Medicine at Mount Sinai | 80 | 2025-04-18 | 2026-05-18 |
| Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation Metformin, Rapamycin, Naltrexone - Longevity, GLP-1 | Phase 2 / Phase 3 | Recruiting | AgelessRx | 150 | 2024-12-17 | 2025-07-30 |
| Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations Sirolimus (RAPAMUNE) - Lymphatic Malformation | Phase 2 / Phase 3 | Recruiting | West China Hospital | 150 | 2024-11-30 | 2024-12-31 |
| Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) Sirolimus Topical Cream, Placebo - Solid Organ Transplant Recipients, Skin Cancer | Phase 3 | Active not recruiting | Melanoma and Skin Cancer Trials Limited | 146 | 2024-02-09 | 2025-09-09 |
| Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex Rapamycin, Placebo - Tuberous Sclerosis Complex | Phase 3 | Recruiting | Katarzyna Kotulska | 200 | 2023-01-23 | 2026-10-22 |
| Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis Sirolimus - Lupus Nephritis, Immunosuppression | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 20 | 2021-06-30 | 2021-05-19 |
| Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Vigabatrin, Rapamycin, Placebo - Tuberous Sclerosis Complex | Phase 2 / Phase 3 | Recruiting | Katarzyna Kotulska | 60 | 2021-05-07 | 2026-10-22 |
| Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus Sirolimus, Placebo - Systemic Lupus Erythematosus | Phase 3 | Active not recruiting | Chinese SLE Treatment And Research Group | 146 | 2021-03-04 | 2025-09-26 |
| Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway Inetetamab, Rapamycin, Pyrotinib - Breast Cancer | Phase 3 | Not yet recruiting | Peking Union Medical College | 270 | 2021-02-02 | 2021-02-03 |
| Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex rapamycin, placebo - Facial Angiofibroma, Tuberous Sclerosis | Phase 2 / Phase 3 | Completed | Dermatology Specialties Limited Partnership | 107 | 2019-07-28 | 2023-09-08 |
| Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer Rapamycin, Placebo Oral Tablet - Bladder Cancer | Phase 3 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2018-11-01 | 2019-06-12 | |
| Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial Sirolimus - LAM, Lymphangioleiomyomatosis | Phase 3 | Active not recruiting | University of Cincinnati | 60 | 2018-01-01 | 2024-12-24 |
| Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome Sirolimus - Sturge-Weber Syndrome | Phase 2 / Phase 3 | Completed | Anne Comi, MD | 10 | 2017-01-01 | 2021-11-01 |
| Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI) - Complication of Renal Dialysis, End Stage Renal Disease | Phase 3 | Completed | Vascular Therapies, Inc. | 269 | 2015-11-01 | 2025-10-09 |
| Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Rapamycin, Placebo - Inclusion Body Myositis (IBM) | Phase 2 / Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 44 | 2015-07-15 | 2025-09-02 |
| Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis Rapamycin, Calcitriol, Rapamycin-calcitriol combination - Facial Angiofibroma | Phase 3 | Completed | National Taiwan University Hospital | 52 | 2013-09-05 | 2017-05-04 |
| Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations Sirolimus - Cardiovascular Abnormalities | Phase 3 | Completed | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 19 | 2012-05-01 | 2016-04-14 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Completed | Fred Hutchinson Cancer Center | 174 | 2010-11-01 | 2026-04-30 |
| Topical Rapamycin for Fibrofolliculomas Rapamycin, placebo - Birt-Hogg-Dubé Syndrome | Phase 3 | Completed | Maastricht University Medical Center | 19 | 2010-01-01 | 2012-03-08 |
Showing 20 of 30. Sign in to see all of them.
Tuberous Sclerosis (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Diabetes Mellitus, Type 1 (2) · Epilepsy (2) · Graft vs Host Disease (2) · Hodgkin Disease (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Acute (2) · Lymphangioleiomyomatosis (2) · Myelodysplastic Syndromes (2) · Skin Neoplasms (2) · Arteriovenous Fistula (1) · Birt-Hogg-Dube Syndrome (1) · Breast Neoplasms (1) · Carcinoma, Squamous Cell (1)
AgelessRx (2) · Katarzyna Kotulska (2) · University of Cincinnati (2) · Anne Comi, MD (1) · Children's Oncology Group (1) · Chinese SLE Treatment And Research Group (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Dana-Farber Cancer Institute (1) · Dermatology Specialties Limited Partnership (1) · Fred Hutchinson Cancer Center (1) · Hoffmann-La Roche (1) · Hospices Civils de Lyon (1) · IRCCS San Raffaele (1) · Icahn School of Medicine at Mount Sinai (1) · Institut National de la Santé Et de la Recherche Médicale, France (1)
United States (16) · France (4) · Australia (3) · Canada (3) · China (3) · Poland (2) · Belgium (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · New Zealand (1)
Stefanie Morgan, PhD (2) · Ali Naji, PhD (1) · Andrew Posselt, MD, PhD (1) · Anne M Comi, M.D. (1) · Antonio Secchi, MD (1) · Bernhard Hering, MD (1) · Brenda Sandmaier (1) · Camillo Ricordi, MD (1) · David Putrino, PT, PhD (1) · Fei Ma, MD (1) · Francis X McCormack, MD (1) · Francis X. McCormack, M.D. (1) · Ioana Stanescu (1) · James Shapiro, MD, PhD (1)
PMID 15061852, PMID 15753371, PMID 21046356, PMID 21180274, PMID 21410393, PMID 22830463, PMID 23438305, PMID 23630300, PMID 24159565, PMID 24497539, PMID 24910976, PMID 24982504, PMID 25629445, PMID 25862561, PMID 25979023, PMID 26729448, PMID 26799509, PMID 27208344, PMID 27465220, PMID 28782106, PMID 29563196, PMID 29654388, PMID 30016177, PMID 30240774, PMID 30846465, PMID 30980684, PMID 31236308, PMID 31248843, PMID 32499241, PMID 34524406, PMID 36044195, PMID 36927115, PMID 37463422, PMID 37717734, PMID 38273639, PMID 38390569, PMID 39578921
P01CA018029 (1), P30CA015704 (1), U01HL069294 (1), U01HL131755 (1), U10CA098543 (1), U54NS065705 (1), U54RR019498 (1)